TIAA CREF Investment Management LLC raised its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 42.2% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,219,961 shares of the biopharmaceutical company’s stock after acquiring an additional 955,578 shares during the period. TIAA CREF Investment Management LLC owned about 1.44% of Alexion Pharmaceuticals worth $391,773,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Guardian Life Insurance Co. of America raised its holdings in Alexion Pharmaceuticals by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 6 shares in the last quarter. Eqis Capital Management Inc. raised its holdings in Alexion Pharmaceuticals by 0.6% in the 2nd quarter. Eqis Capital Management Inc. now owns 6,776 shares of the biopharmaceutical company’s stock valued at $824,000 after acquiring an additional 38 shares in the last quarter. Rathbone Brothers plc raised its holdings in Alexion Pharmaceuticals by 2.5% in the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 50 shares in the last quarter. Cleararc Capital Inc. raised its holdings in Alexion Pharmaceuticals by 1.0% in the 1st quarter. Cleararc Capital Inc. now owns 5,495 shares of the biopharmaceutical company’s stock valued at $666,000 after acquiring an additional 53 shares in the last quarter. Finally, Seven Bridges Advisors LLC raised its holdings in Alexion Pharmaceuticals by 2.1% in the 2nd quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after acquiring an additional 53 shares in the last quarter. 94.26% of the stock is owned by hedge funds and other institutional investors.

In other Alexion Pharmaceuticals news, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the sale, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the sale, the director now directly owns 6,315 shares in the company, valued at approximately $869,828.10. The disclosure for this sale can be found here. In the last three months, insiders purchased 2,019,734 shares of company stock worth $235,606,846 and sold 17,070 shares worth $2,416,869. Insiders own 4.35% of the company’s stock.

WARNING: “TIAA CREF Investment Management LLC Purchases 955,578 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/12/tiaa-cref-investment-management-llc-purchases-955578-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down 1.15% on Tuesday, hitting $141.29. The stock had a trading volume of 1,073,210 shares. The company has a 50 day moving average of $137.04 and a 200 day moving average of $124.11. The company has a market capitalization of $31.53 billion, a PE ratio of 61.27 and a beta of 1.40. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912.00 million for the quarter, compared to analysts’ expectations of $846.15 million. During the same quarter in the previous year, the firm posted $1.13 earnings per share. Alexion Pharmaceuticals’s revenue for the quarter was up 21.1% on a year-over-year basis. On average, equities analysts expect that Alexion Pharmaceuticals, Inc. will post $5.61 earnings per share for the current year.

Several research firms have commented on ALXN. UBS AG reaffirmed a “buy” rating and issued a $140.00 price target (down previously from $143.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, May 31st. SunTrust Banks, Inc. reissued a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Leerink Swann reissued a “buy” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, May 23rd. BidaskClub raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Jefferies Group LLC set a $120.00 target price on Alexion Pharmaceuticals and gave the stock a “hold” rating in a report on Thursday, June 8th. Five investment analysts have rated the stock with a hold rating, twenty have given a buy rating and three have given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $156.32.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.